Background {#Sec1}
==========

Osteoarthritis (OA) is the most common joint disease worldwide, and primarily affects the knees, hips, hands, and spine. It is a leading cause of disability among older individuals and also affects their quality of life \[[@CR1]\]. It is characterized by the progressive degeneration of articular cartilage, and by subchondral sclerosis resulting in pain and joint stiffness \[[@CR2]\].

The etiology of OA is multifactorial, including genetic and environmental risk factors. Associated genes include *GDF5* \[[@CR3]\], *ASPN* \[[@CR4]\], *FRZB* \[[@CR5]\], and *COL2A1* \[[@CR6]\], while environmental factors may include obesity \[[@CR7]-[@CR9]\], history of knee injury \[[@CR10]\], occupational activities \[[@CR11],[@CR12]\], sex hormones and structural changes \[[@CR13]\], meniscectomy \[[@CR14]\], gender, and age \[[@CR15]\]. Twin-pair and family genetic data show that more than 50% of OA can be attributed to genetic factors \[[@CR16]\]. A gender difference is also apparent, with females having a greater prevalence of OA after the age of 50 years \[[@CR17]\]. Additionally, the disease is more common among European populations \[[@CR18]\]. The observation that the estrogen receptor (ER) is expressed in human articular chondrocytes and bone cells suggests that it may be involved in the etiology of OA \[[@CR19]\].

The ER has two isoforms: ERα and ERβ. *ERα* expression affects the growth of bone cells, while *ERβ* participates in the formation and resorption of bone \[[@CR20]\]. *ERα* is located on chromosome 6q25.1 and contains eight exons and seven introns \[[@CR21]\], as well as two common restriction fragment length polymorphisms (RFLPs): *Xba*I and *Pvu*II. The *Xba*I RFLP detects an A--G substitution at position 351 (−351int A/G; rs9340799), while *Pvu*II detects a T--C substitution at position 397 (−397int T/C; rs2234693). A previous meta-analysis confirmed the association between bone mineral density and *ERα* \[[@CR22]\].

A number of studies have investigated the association between *ERα* polymorphisms and the risk of OA in different populations, but the results are inconsistent. Some discovered that *ERα* polymorphisms were associated with an increased risk of OA \[[@CR23]-[@CR28]\], while others found no association with OA risk \[[@CR28],[@CR29]\], or an association with a reduced risk of OA \[[@CR30]-[@CR34]\]. To our knowledge, no systematic review has examined the evidence for a relationship between *ERα* polymorphisms and OA. Therefore, we conducted a meta-analysis to analyze the association between *ERα* polymorphisms and OA susceptibility.

Methods {#Sec2}
=======

This systematic review was conducted according to 2009 PRISMA guidelines \[[@CR35]\].

Search strategy {#Sec3}
---------------

We performed a systematic research of available studies that assessed the association between *ERα* polymorphisms and OA. We carried out a comprehensive literature search for published studies in OVID MEDLINE, EMBASE, CBM, and PubMed databases, and Google Scholar. Primary key search terms included estrogen receptor, polymorphism, osteoarthritis, and OA. Index terms for OVID MEDLINE were: "estrogen receptor", "polymorphism", and "osteoarthritis" or "OA". The last query was updated on 30 November 2014. There were no language or other limitations on the search. Reference lists in the retrieved articles or relevant reviews were also screened to identify other eligible studies. We also searched unpublished studies by contacting clinical experts and the Arthritis Foundation National Office. A flow diagram of our literature identification strategy is shown in Figure [1](#Fig1){ref-type="fig"}.Figure 1**Flow diagram of study selection according to the PRISMA statement.**

Inclusion and exclusion criteria {#Sec4}
--------------------------------

Eligible studies were required to satisfy the following criteria: (1) the study was a cohort or a case--control study; (2) OA was diagnosed based on clinical criteria defined by the American College of Rheumatology; (3) the original study assessed the association between *ERα* polymorphisms (*Xba*I or *Pvu*II) and OA susceptibility; and (4) the study provided sufficient genetic frequency or sufficient data for extraction. If overlapping study populations were identified between studies, only the most complete one was included in the meta-analysis. Animal studies and literature reviews were excluded.

Quality assessment of included studies {#Sec5}
--------------------------------------

Study quality was independently assessed by two authors, based on the Newcastle--Ottawa scale (NOS) quality score systems \[[@CR36]\]. The NOS contains eight items divided into three categories: selection, comparability, and outcome (for cohort studies) or exposure (for case--control studies). Quality scores ranged from 0 to 9. When there was disagreement on the quality scores between the two authors, discrepancies were resolved through discussion and consultation with a third author.

The quality of included studies was also assessed by the Hardy--Weinberg equilibrium (HWE) for the control genotype distribution. Studies consistent with HWE were defined as high-quality, while those inconsistent with HWE were defined as low-quality studies.

Data extraction {#Sec6}
---------------

The following data were extracted from each full-text study using a standardized data extraction form: the name of the first author, year of publication, country in which the study was performed, study design, number of cases and controls, gender, age, genotyping, OA site, OA definition, polymorphism, and numbers of cases and controls for each of the *Pvu*II (rs2234693), and *Xba*I (rs9340799) genotypes. When the information extracted from studies was inconsistent, disagreement was resolved through discussion and consultation with a third author until consensus was achieved on every item.

Statistical analysis {#Sec7}
--------------------

STATA 12.0 and Review Manager 5.2 software were used for data analysis. The pooled odds ratio (OR) and its 95% confidence interval (95% CI) were calculated to assess the association between *ERα* polymorphisms and the risk of OA for the following contrasts: G vs. A, AG vs. AA + GG, GG vs. AG + AA, AA vs. AG + GG, C vs. T, CC vs. TT + CT, CT vs. CC + TT, and TT vs. CC + CT. Subgroup analysis based on ethnicity was also performed. The Chi-square test was used to determine if the identified study was consistent with HWE for the control genotype distribution. Heterogeneity between studies was evaluated with the *I*^2^ test and the *Q* statistic. We used the Cochrane system for heterogeneity grading: *I*^2^ 0--40%, might not be important; 30--60%, moderate heterogeneity; 50--90%, substantial heterogeneity; 75--100%, considerable heterogeneity. Heterogeneity was assessed to be significant when *I*^2^ \> 30% or when *P* \< 0.1 for *Q* statistics.

The pooled effects were estimated using the Der-Simonian and Laird method for random effects and the Mantel--Haenszel method for fixed effects \[[@CR37]\]. If the studies were significantly heterogeneous, we used the random effects model. Otherwise, we used the fixed effects model to calculate the pooled OR and 95%CI. The random effects model assumes that different studies have substantial diversity and assesses both within-study sampling error and between-study variation \[[@CR38]\]. The fixed effects model assumes that genetic factors have similar effects on OA susceptibility across all studies, and that observed variations between studies are caused by chance alone \[[@CR39]\]. Sensitivity analyses were performed for the effect size omitting the trial for which data were imputed, and were used to evaluate the stability of the results. Publication bias was graphically represented by funnel plots and further evaluated with the Begg's test and Egger's test \[[@CR40],[@CR41]\].

Results {#Sec8}
=======

Search results and studies included in the meta-analysis {#Sec9}
--------------------------------------------------------

Seventy-seven relevant studies were preliminarily identified in the database search, of which 11 \[[@CR24]-[@CR34]\] eventually satisfied the eligibility criteria for our meta-analysis. All included studies investigated the relationship between *ERα* polymorphisms and OA susceptibility. Of these, one study \[[@CR33]\] contained data on three different OA sites and four different geographical locations, so these seven comparisons were treated independently. Therefore, a total of 17 separate comparisons were included in the present meta-analysis. Ten studies with a total of 8,502 participants (2,181 OA patients and 6,321 controls), which involved three European and seven Asian populations, evaluated the association between the *ERα Xba*I polymorphism and OA susceptibility, while 17 with 16,159 total participants (5,325 OA patients and 10,834 controls), involving 10 European and seven Asian populations, evaluated the association between the *ERα Pvu*II polymorphism and OA susceptibility. Study characteristics are summarized in Table [1](#Tab1){ref-type="table"}.Table 1**Characteristics of the included studiesStudy \[Ref.\]YearCountry (City)Study designGenotypingNumbersGender (M/F)AgePolymorphism (s)Quality scoreOAControlOAControlOAControl**Toshio Ushiyama et al. \[[@CR24]\]1998JapanCase--controlPCR653180/650/31868.5 (49--86)49-86XbaI, PvuII7 (2/2/3)John Loughlin et al. \[[@CR29]\]2000UK (Oxford)Case--controlPCR371369155/216221/14873 (56--90)73 (59--89)XbaI, PvuII8 (3/2/3)Barton L. Wise et al. \[[@CR30]\]2009USACohortPCR307214258/26361 ± 9XbaI8 (4/2/2)Barton L. Wise et al. \[[@CR30]\]2009USACohortPCR304211253/26261 ± 9PvuIIV. M. Borgonio-Cuadra et al. \[[@CR32]\]2012MexicoCase--controlPCR11511723/9220/9757.4 ± 9.251.8 ± 8.9XbaI, PvuII9 (4/2/3)J. A. Riancho et al. \[[@CR33]\]2010Spain (Santander)Case--controlPCR27280295/177285/51772 ± 771 ± 10PvuII8 (3/2/3)J. A. Riancho et al. \[[@CR33]\]2010Spain (Santiago)Case--controlPCR25447347/207295/17868 ± 668 ± 9PvuIIJ. A. Riancho et al. \[[@CR33]\]2010UK (Oxford)Case--controlPCR445862176/269471/39164 ± 569 ± 7PvuIIJ. A. Riancho et al. \[[@CR33]\]2010Spain (Santander)Case--controlPCR359802180/179285/51771 ± 771 ± 10PvuIIJ. A. Riancho et al. \[[@CR33]\]2010Spain (Coruña)Case--controlPCR25224490/16297/14767 ± 1465 ± 13PvuIIJ. A. Riancho et al. \[[@CR33]\]2010Spain (Santiago)Case--controlPCR287473110/177295/17868 ± 568 ± 9PvuIIJ. A. Riancho et al. \[[@CR33]\]2010UK (Oxford)Case--controlPCR1278862503/775471/39165 ± 669 ± 7PvuIIK. Lian M.D. et al. \[[@CR31]\]2007USACohortPCR56941340/5690/413479.6 ± 5.078.4 ± 4.6XbaI, PvuII8 (4/2/2)Sheng-Yu Jin et al. \[[@CR25]\]2004KoreaCase--controlPCR15139753/98190/20758.8 ± 9.6/XbaI, PvuII8 (3/2/3)Zhi Tian et al. \[[@CR28]\]2009ChinaCase--controlPCR38400/380/4059.2 ± 3.258.5 ± 8.6XbaI, PvuII7 (2/2/3)Jiexiang Yang et al. \[[@CR34]\]2009ChinaCase--controlPCR414031/5054.6 (28--82)XbaI, PvuII6 (2/1/3)Yan Xue et al. \[[@CR27]\]2004ChinaCase--controlPCR551760/550/17658.7 ± 2.460 ± 10XbaI, PvuII7 (3/1/3)Xiaoyu Dai et al. \[[@CR26]\]2014ChinaCase--controlPCR469522113/356398/12457.3 ± 10.956.4 ± 9.8XbaI, PvuII7 (3/1/3)

Allele and genotype counts {#Sec10}
--------------------------

Allelic counts of the *ERα Xba*I polymorphism were evaluated for G and A alleles. In general, the frequency of the A allele was higher in OA cases than in controls. Genotype counts of the *ERα Xba*I polymorphism were evaluated for GG, AG, and AA genotypes, and the frequency of the AA genotype was higher in OA cases than in the control group in all but one study \[[@CR24]\]. The frequency of the AG genotype was lower in OA cases than in the control group in all but the same study \[[@CR24]\]. There was no obvious difference in the frequency of the GG genotype between OA cases and controls. Allele and genotype counts for the *ERα Xba*I polymorphism in cases and controls are shown in Table [2](#Tab2){ref-type="table"}.Table 2**Genotype and allele counts for the** ***ERα Xba*** **I polymorphism in the included studiesGroupStudyCountryOA siteX (G)x (A)xx (AA)Xx (AG)XX (GG)OAControlOAControlOAControlOAControlOAControl**EuropeanBarton L. Wise et al.USAHand20215941226914885116994330John Loughlin et al.UKHip,Knee2562514864871641611581654943K. Lian M.D. et al.USAHip374291476453322571700250193262491European Total83233241662608856919465242196154564AsianSheng-Yu Jin et al.KoreaKnee571562456389825649126415Toshio Ushiyama et al.JapanHand3011610052036211289819V. M. Borgonio-Cuadra et al.MexicoKnee49631811717062414748Zhi Tian et al.ChinaKnee244752331861621413Jiexiang Yang et al.ChinaKnee151967612824111323Yan Xue et al.ChinaKnee4420066162214024821054Xiaoyu Dai et al.ChinaKnee2101937288512883481521552919Asian Total4297941439243655994732154254121Total1261411831018524112828938452738208685

Allelic counts of the *ERα Pvu*II polymorphism were evaluated for C and T alleles. In general the T allele frequency was higher in OA cases than in the control group. Genotype counts of the *ERα Pvu*II polymorphisms were evaluated for TT, CT, and CC genotypes, and the TT genotype frequency was generally higher in OA cases than in controls. The CC genotype frequency was generally lower in OA cases than controls, although there was no obvious difference in the frequency of the CT genotype between the two groups. Allele and genotype counts for the *ERα Pvu*II polymorphism in cases and controls are shown in Table [3](#Tab3){ref-type="table"}.Table 3**Genotype and allele counts for the** ***ERα Pvu*** **II polymorphism in the included studiesGroupStudyCoutry (City)OA siteP (C)p (T)pp (TT)Pp (CT)PP (CC)OAControlOAControlOAControlOAControlOAControl**EuropeanBarton L. Wise et al.USAHand261192347230101651451005846J. A. Riancho et al.Spain (Coruña)Hip21321729127189761131195049J. A. Riancho et al.UK (Oxford)Hip11097761447948426253595442257167J. A. Riancho et al.UK (Oxford)Knee39977649194812325324544277167J. A. Riancho et al.Spain (Santander)Hip33475238485210522917439480179J. A. Riancho et al.Spain (Santander)Knee2467522988527922914039453179J. A. Riancho et al.Spain (Santiago)Knee235377273569651761432174680J. A. Riancho et al.Spain (Santiago)Hip239377335569991761372175180John Loughlin et al.UKHip,Knee3313314114071141101831877472K. Lian M.D et al.USAHip4813835653439118811622772067102884European Total3848838549301003713892729215245798481903AsianSheng-Yu Jin et al.KoreaKnee11230719048761152681832262Toshio Ushiyama et al.JapanHand572607337619115351461157V. M. Borgonio-Cuadra et al.MexicoKnee7782153152525149501416Zhi Tian et al.ChinaKnee293447461615151679Jiexiang Yang et al.ChinaKnee3733454714121723105Yan Xue et al.ChinaKnee5315157201175723871532Xiaoyu Dai et al.ChinaKnee3873905516381671982172428574Asian Total752125711161947346600424747164255Total46009642604611984173533292576532610122158

Quality assessment of included studies {#Sec11}
--------------------------------------

All 11 studies had a satisfactory NOS quality score as shown in Table [1](#Tab1){ref-type="table"}. The distribution of genotypes in the controls was in accordance with HWE (*P* \> 0.05) in all studies, so all were classed as high-quality.

Meta-analysis findings {#Sec12}
----------------------

A summary of the meta-analysis findings are shown in Table [4](#Tab4){ref-type="table"}. The *ERα Xba*I polymorphism was shown not to be associated with OA risk in all populations (G vs. A: OR = 0.87, 95% CI = 0.73--1.04, *P* = 0.13; AA vs. AG + GG: OR = 1.16, 95% CI =0.94--1.44, P = 0.17; AG vs. AA + GG: OR = 0.93, 95% CI =0.84--1.04, *P* = 0.22; GG vs. AG + AA: OR = 0.88, 95% CI =0.67--1.17, *P* = 0.38). However, subgroup analysis by ethnicity showed that the AA and AG genotypes of the *ERα Xba*I polymorphism were associated with OA risk among Europeans (AA vs. AG + GG: OR = 1.17, 95% CI = 1.02--1.34, *P* = 0.03; AG vs. AA + GG: OR = 0.86, 95% CI = 0.75--0.99, *P* = 0.04), but not among Asian populations (Figure [2](#Fig2){ref-type="fig"}).Table 4**Meta-analysis of** ***ERα Xba*** **I and** ***Pvu*** **II polymorphisms and OA susceptibilityPolymorphism comparisonPopulation OA siteNo. of studiesTest of associationTest of heterogeneityTest of publication biasBegg\'s testEgger\'s testOR95%** ***CI**p*** **-valueModelQ test*p*** **-value*I*** ^**2**^**Z test*p-value*T test*p-value*XbaI** (G vs. A)Overall100.870.73---1.040.13Random29.710.000570%−0.800.42−1.290.23European30.910.82---1.010.08Fixed1.670.430%Asian70.800.57---1.130.21Random27.740.000178%AA vs. AG + GGOverall101.160.94---1.440.17Random25.550.00265%1.160.250.940.38European31.171.02---1.340.03Fixed1.910.390%Asian71.220.84---1.790.30Random21.690.00172%AG vs. AA + GGOverall100.930.84---1.040.22Fixed10.610.3015%0.090.930.470.65European30.860.75---0.990.04Fixed1.520.470%Asian71.060.89---1.260.52Fixed5.870.440%GG vs. AG + AAOverall100.880.67---1.170.38Random14.230.1137%−0.800.421.890.10European30.970.79---1.200.81Fixed0.850.650%Asian70.650.36---1.190.17Random12.580.0552%**PvuII** (C vs. T)Overall170.980.93---1.030.37Fixed19.580.2418%0.660.510.870.40European100.970.90---1.040.14Random13.610.1434%Asian71.070.95---1.210.25Fixed3.190.780%CC vs. TT + CTOverall170.970.89---1.060.55Fixed13.090.670%0.080.930.260.80European100.940.85---1.040.21Fixed5.050.830%Asian71.170.94---1.470.16Fixed4.940.550%CT vs. CC + TTOverall170.990.92---1.060.75Fixed19.850.2319%0.410.680.730.48European101.010.91---1.130.82Random15.430.0842%Asian70.960.81---1.140.64Fixed4.290.640%TT vs. CC + CTOverall171.010.92---1.120.79Random23.830.0933%−0.250.81−1.150.27European101.020.90---1.170.74Random20.330.0256%Asian70.950.80---1.130.57Fixed2.350.880%Figure 2**Meta-analysis of the association between the** ***ERα Xba*** **I polymorphism and OA (AG vs. AA + GG).**

There was no significant association between the *ERα Pvu*II polymorphism and susceptibility to OA in all populations (C vs. T, OR = 0.98, 95% CI = 0.93--1.03, *P* = 0.37; CC vs. TT + CT, OR = 0.97, 95% CI = 0.89--1.06, *P* = 0.55; CT vs. CC + TT, OR = 0.99, 95% CI = 0.92--1.06, *P* = 0.75; TT vs. CC + CT, OR = 1.01, 95% CI = 0.92--1.12, *P* = 0.79). In the subgroup analysis based on ethnicity, no significant association was found for the *ERα Pvu*II polymorphism in either European or Asian populations (Figure [3](#Fig3){ref-type="fig"}).Figure 3**Meta-analysis of the association between the** ***ERα Pvu*** **II polymorphism and OA (CC vs. TT + CT).**

Sensitivity analysis and publication bias {#Sec13}
-----------------------------------------

As shown in Table [4](#Tab4){ref-type="table"}, heterogeneity was observed among studies in all populations and also in subgroup analyses. To explore the sources of heterogeneity across studies we performed a sensitivity analysis, which revealed that none of the studies significantly affected the pooled ORs and CIs. Sequential removal of each study had little effect on the pooled ORs.

The funnel plot revealed no obvious publication bias (Figure [4](#Fig4){ref-type="fig"}), and this was confirmed by Begg's test and Egger's test.Figure 4**Funnel plot of the meta-analysis of the ERα PvuII polymorphism with susceptibility to OA (C vs. T).**

Discussion {#Sec14}
==========

Although the pathogenesis of OA is considered to be the result of many factors, genetics are thought to be one of the most important determinants \[[@CR42]\]. Despite the fact that *ERα* is one of the most studied genes in OA \[[@CR43]\], to the best of our knowledge this is the first meta-analysis of the relationship between *ERα* polymorphisms *Xba*I and *Pvu*II and OA risk.

Our meta-analysis included 11 published studies (with 17 comparisons) of 16,159 participants (5,325 OA patients and 10,834 controls). Ten studies with a total of 8,502 participants evaluated the association between the *ERα Xba*I polymorphism and OA susceptibility, and our meta-analysis suggested that it was significantly associated with OA in European but not Asian populations. The pooled OR for homozygote AA carriers showed that they were associated with a 17% increased risk for OA compared with AG and GG carriers, and that European AG carriers had a decreased OA risk. The heterogeneity of genetic effects between European and Asian populations suggests the existence of gene--environment or gene--gene interactions. No heterogeneity was detected in European populations with respect to the *ERα Xba*I polymorphism and OA, suggesting that the genetic effect of this polymorphism is stronger in European than Asian populations.

Seventeen studies with a total of 16,159 participants evaluated the association between the *ERα Pvu*II polymorphism and OA susceptibility. Our meta-analysis suggested that there was no association between the polymorphism and susceptibility to OA in any population. The same result was obtained for the subgroup analysis based on ethnicity.

Gender differences are known to affect the development of OA; for example, the prevalence of knee OA is greater in women than men \[[@CR15]\]. Only two of the studies included in our meta-analysis were stratified according to participant gender \[[@CR25],[@CR32]\], and both reported no significant differences in the *ERα* polymorphisms between OA patients and controls of the same sex. However, because of the small number of this type of study and the limited raw data based on gender differences in genotype distributions and allele frequencies, we were unable to perform a subgroup analysis according to gender.

Several limitations should be taken into consideration in the current meta-analysis. First, it was based on unadjusted OR estimates because not all studies presented adjusted ORs, or the ORs were not adjusted by the same potential confounders, such as age and gender. This lack of information could have caused serious confounding bias. Second, OA is influenced by both genetic and environmental risk factors such as obesity, injury, occupational activities, and meniscectomy. However, the studies included in the meta-analysis did not control for these environmental risk factors. Third, some studies included individuals with OA in different sites, but we were unable to perform subgroup analysis of this within the same ethnic population because of the limited available data. For instance, hand OA is known to be more influenced by genetic and hormonal influences than other types of OA, but the relationship between the *ERα Xba*I polymorphism and hand OA was only reviewed in one study of Europeans \[[@CR30]\] and one of Asians \[[@CR24]\]. Other studies of the *ERα Xba*I polymorphism and OA susceptibility in Europeans focused on three different OA sites. Finally, although our current findings suggest that the *ERα Xba*I polymorphism is associated with OA in Europeans, it was not possible to determine whether this polymorphism is in linkage disequilibrium with any other potentially functional polymorphisms. However, our meta-analysis also had some advantages, including a satisfactory quality of all 11 included studies, and a well-designed method.

Conclusions {#Sec15}
===========

The present results suggest that there may be a weak relationship between the *ERα Xba*I polymorphism and OA in European but not Asian populations, while the *ERα Pvu*II polymorphism did not appear to be associated with OA in either Europeans or Asians. Because the studies included in the meta-analysis reviewed the relationship between the *ERα Xba*I polymorphism and OA susceptibility at three different sites in Europeans, large well-designed studies are necessary to confirm our findings in more homogeneous populations.
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